# Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

> **NCT03025958** · PHASE2 · COMPLETED · sponsor: **Zhejiang Cancer Hospital** · enrollment: 30 (actual)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Nimotuzumab
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT03025958
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-13
- **Primary completion:** 2018-11-12
- **Final completion:** 2023-12-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03025958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03025958, "Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03025958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*